CLINICAL_TRIALS
trial_result
· 2017-06-05
Clinical Trial Update: Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) [Phase 3]
Summary
Phase 3 extension study of eculizumab in transfusion-dependent paroxysmal nocturnal hemoglobinuria has completed and posted results in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Hemoglobinuria, Nocturnal | Phase 3 | Status: COMPLETED | Results posted: 2017-06-05